Everolimus

Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan

Japan Submission Includes Clinical Data Demonstrating Superiority of XIENCE V Compared to TAXUS(R) Drug Eluting Stent TOKYO, June 2 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced that it has submitted an application for Seizo Hanbai Shonin (Marketing Authorization L...

NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus

NCCN has added everolimus (Afinitor(R), Novartis) to the NCCN Guidelines for Kidney Cancer as a recommended treatment for patients with renal cell carcinoma whose disease has progressed after treatment with kinase inhibitors. This recommendation comes on the heels of the March 30, 2009 FDA approva...

Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009

... Initiated Trial of Next-Generation XIENCE PRIME(TM) Drug-Eluting Stent: Announced CE Mark for Abbott's next-generation XIENCE PRIME everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. Abbott is launching XIENCE PRIME in a broad size matrix with lengths up to...

Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position

...ropeenne) for its next-generation XIENCE PRIME(TM) everolimus Eluting Coronary Stent System for the treatment of...ble polymer as Abbott's market-leading XIENCE V(R) everolimus Eluting Coronary Stent System. In addition, it off...tt by Novartis for use on its drug eluting stents. everolimus has been shown to inhibit in-stent neointimal grow...

Newest Coated Stent Does Well in Real-World Trial

...ort. The Xience stent -- a flexible metal-mesh tube coated with the drug everolimus -- is inserted to keep blood flowing after artery-opening procedures such a... Xience stent is used in "50 to 60 percent of that 75 percent," he said. everolimus is a more potent drug than those used in the first-generation coated stents...

Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials

... of the company's next-generation XIENCE PRIME(TM) everolimus Eluting Coronary Stent System, currently an invest...ble polymer as Abbott's market-leading XIENCE V(R) everolimus Eluting Coronary Stent System. In addition, it off...ns to study more than 20,500 patients treated with everolimus eluting stents. In addition to SPIRIT PRIME,...

Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study

...tudy show that Abbott's market-leading XIENCE V(R) everolimus Eluting Coronary Stent System demonstrated low rat...eluting stent in development, the XIENCE PRIME(TM) everolimus Eluting Coronary Stent System, utilizes the same d...tt by Novartis for use on its drug eluting stents. everolimus has been shown to inhibit in-stent neointimal grow...

Abbott Announces EuroPCR 2009 Activities

... study of the company's market-leading XIENCE V(R) everolimus Eluting Coronary Stent System, as well as new deta...eluting stent in development, the XIENCE PRIME(TM) everolimus Eluting Coronary Stent System. During the mee...tt by Novartis for use on its drug eluting stents. everolimus has been shown to inhibit in-stent neointimal grow...

Mayo Clinic researchers formulate treatment combination lethal to pancreatic cancer cells

...leagues remain focused on trying to understand the mechanism for how these agents together are so powerful. Rapamycin and a closely related drug, everolimus (RAD001), have both been tested in pancreatic cancer cells, but by themselves have shown minimal activity, Dr. Gupta says. They belong to a class of a...

Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease

... eluting coronary device; and the XIENCE PRIME(TM) everolimus Eluting Coronary Stent System, which builds on the...performance of Abbott's market-leading XIENCE V(R) everolimus Eluting Coronary Stent System. EMBOSHIELD N...tt by Novartis for use on its drug eluting stents. everolimus has been shown to inhibit in-stent neointimal grow...

Everolimus in Medical Technology

Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial

One-year Data Demonstrate Continued Safety, Consistently Positive Clinical Results with XIENCE V WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT III U.S. pivotal clinical trial demonstrated continued positive, statistically signifi...

Abbott's Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial

- XIENCE V Demonstrates Superiority in Primary Endpoint of In-Segment Late Loss, Non-Inferiority in Major Secondary Endpoint of Target Vessel Failure and Superiority in Major Adverse Cardiac Events (MACE) in the SPIRIT III U.S. Trial - ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ -- Da...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...th relapsed NHL and Hodgkin's disease treated with everolimus experienced a 50% or greater reduction in tumor si...se III trial investigating adjuvant treatment with everolimus (RAD001) in poor-risk patients with DLBCL who achi...his worldwide study will evaluate the potential of everolimus to extend disease-free survival in patients with D...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

...F receptor inhibitor (sunitinib or sorafenib) and an mTOR inhibitor (either everolimus or temsirolimus). For this group, best response and median PFS to single a...tastatic RCC (VEGF inhibitors, sunitinib and sorafenib, and mTOR inhibitors everolimus and temsirolimus), the National Cancer Institute reports a rising incidence...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...nced HCC, the stage when most are diagnosed(4)(5). everolimus shows potential to help address this unmet medical...he 31 patients evaluable in the trial, 16 received everolimus (known as RAD001 in this study) daily. The study o...global Phase III clinical trial to study the daily everolimus regimen in patients with advanced HCC is in develo...

Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent

...ies is intended to provide a full range of DES solutions for interventional cardiologists, giving them the option to treat patients with a paclitaxel, everolimus or bare-metal stent. In my experience, the TAXUS Element Stent is a highly deliverable and conformable platform that has the potential to simplify co...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

...oot/CRI/content/ CRI_2_4_3X_How_is_kidney_cancer_staged_22.asp?rnav=cri. Accessed March 2009. Escudier, B. et al. Phase-3 randomized trial of everolimus (RAD001) vs. placebo in metastatic renal cell carcinoma. Presented at the European Society for Medical Oncology (ESMO) 33rd Congress on September 16, ...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

...ed that the clinical advantages of the XIENCE V(R) everolimus Eluting Coronary Stent System continued to increas...d. Abbott's next-generation XIENCE PRIME(TM) everolimus Eluting Coronary Stent System utilizes the same dr...tt by Novartis for use on its drug eluting stents. everolimus has been shown to inhibit in-stent neointimal grow...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

... patients demonstrated that Abbott's bioabsorbable everolimus eluting stent successfully treated coronary artery...rug eluting coronary stent. Abbott's bioabsorbable everolimus eluting coronary device is made of polylactic acid...tem for carotid stenting; and the XIENCE PRIME(TM) everolimus Eluting Coronary Stent System, which builds upon t...

The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent

...ary stent out to two years. Abbott's bioabsorbable everolimus eluting coronary device is made of polylactic acid...t XIENCE V Abbott's market-leading XIENCE V(TM) everolimus Eluting Coronary Stent System was approved by the ...tt by Novartis for use on its drug eluting stents. everolimus has been shown to inhibit in-stent neointimal grow...

Everolimus in Biological News

The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent

... These one year results for Abbott's bioabsorbable everolimus eluting stent were consistent with performance dem...ll safety and performance of a fully bioabsorbable everolimus eluting stent out to 5 years. "Abbott's bioabsorbable everolimus eluting stent has demonstrated excellent clinical ...

Everolimus in Biological Technology

Boston Scientific Acquires Labcoat Limited

...echnology is planned following regulatory approval. Boston Scientific plans to evaluate the Labcoat technology for use on both its paclitaxel and everolimus families of drug-eluting stents. Paclitaxel is employed on the TAXUS(R) family of stents, which have been studied in thousands of patients in cli...

Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award

...oped by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties. ...

Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent

...oped by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties. ...

FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent

... that the U.S. Food and Drug Administration (FDA) approved the XIENCE(TM) V everolimus Eluting Coronary Stent System for the treatment of coronary artery disease....hibitor, licensed to Abbott by Novartis for use on its drug eluting stents. everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessel...

The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

...sorbable everolimus eluting stent out to 5 years. "Abbott's bioabsorbable everolimus eluting stent has demonstrated excellent clinical safety out to one year in...arget lesion revascularization) in the ABSORB trial. Abbott's bioabsorbable everolimus eluting stent also demonstrated 100 percent procedural success and 94 perce...

A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)

... the simultaneous determination of four immunosuppressant drugs: Cyclosporin A (CsA), Tacrolimus (TAC, aka FK-506), Sirolimus (SIR, aka Rapamycin) and everolimus (EVE, aka RAD-001) (1, 2). The method is based on a simple and robust hardware configuration and shows to be fast and simple, without compromising pre...